Dupixent (dupilumab)

pCPA File Number: 21055

Negotiation Status:

Concluded with an LOI

Indication(s):

Atopic dermatitis

Sponsor/Manufacturer:

Sanofi Genzyme Canada

CDA-AMC Project Number:

SR0533-000

pCPA Engagement Letter Issued:

2018-11-22

Negotiation Process Concluded:

2019-09-17